LivaNova Plc Q1 FY2026 earnings call

Management noted 11% revenue growth in the quarter driven by cardiopulmonary and epilepsy businesses. Progress in OSA market with FDA approval of Aura 6000 system and positive clinical results of Osprey trial. Innovation updates in OSA including PolySync progress and in epilepsy with rollout of cloud-based clinician portal.

Cardiopulmonary segment: Revenue was $209 million in the quarter, an increase of 14% versus Q1 2025. For full year 2026, expected cardiopulmonary revenue growth of 8.5% to 9.5%. Epilepsy segment: Revenue increased 8% versus Q1 2025. Full year 2026 epilepsy revenue growth expected 6% to 7%.

Full year 2026 revenue growth expected 7% to 8% on constant currency, up from 6% to 7% previously. Adjusted diluted EPS expected in range of $4.20 to $4.30. Adjusted free cash flow expected 160 to $180 million.

Impact of ~$5 million on adjusted operating income from Middle East conflict related to shipping and fuel costs. Tariff net impact less than $5 million. Supply chain challenges with third-party components.

Q: Expand on epilepsy business post reimbursement change?

A: Rick, great to hear your voice and thank you for the question...

Q: Competitive landscape on oxygenators?

A: Mike, we see competitors exiting from the space and no capacity expansion from other competitors.